Annual report
4502.TEDINET S100R3K7
Period2022-04-01 → 2023-03-31
Filed2023-06-28
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.03T | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥3.57T | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥3.20T | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥3.29T | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥2.10T | 2018-04-01 → 2019-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥490.5bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥460.8bn | 2021-04-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥375.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥302.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥366.2bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥60.8bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥127.6bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥317.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥230.1bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥376.0bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥44.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥135.2bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥317.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥230.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥376.2bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥44.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥135.1bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Total assets | ¥13.96T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥13.18T | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥12.91T | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥12.82T | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥13.79T | at 2019-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥7.60T | at 2023-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥7.49T | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥6.35T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥5.68T | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥5.18T | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥6.35T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥5.68T | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Cash & equivalents | ¥533.5bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥849.7bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥966.2bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥637.6bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥702.1bn | at 2019-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥977.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥1.12T | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥1.01T | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥669.8bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥328.5bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥607.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥198.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥393.5bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥292.1bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥2.84T | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥709.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥1.07T | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥1.09T | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥1.01T | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥2.95T | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥204.29 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥147.14 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥240.72 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥28.41 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥140.61 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥201.94 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥145.87 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥238.96 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥28.25 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥139.82 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥4,087.49 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥3,665.61 | at 2022-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥3,308.93 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥3,032.22 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥3,332.94 | at 2019-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 45.5% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 43.1% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 40.1% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 36.8% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 37.6% | at 2019-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 5.3% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 4.2% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 7.6% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 0.9% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 3.8% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 49,095 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 47,347 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 47,099 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 47,495 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 49,578 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥632.1bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥764.3bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥602.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥616.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥651.3bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥136.1bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥293.7bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥340.1bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥550.9bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥50.0bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥72.3bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.5bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥383.0bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥371.9bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥330.6bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥324.4bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥247.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥130.6bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥88.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥9.41T | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥9.64T | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥10.86T | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥10.29T | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥9.53T | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥5.20T | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥5.35T | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥4.21T | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥4.29T | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥4.43T | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥4.55T | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.65T | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥164.9bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥287.1bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥213.06 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥207.5 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥158.45 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥83.88 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥91.76 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥213.05 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥207.5 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥158.44 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥83.87 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥91.72 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥180 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥180 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥180 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥180 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥180 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,704.87 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,769.31 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,835.81 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,919.21 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,987.94 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 44.7% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.5% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.8% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.2% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.7% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 7.8% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.4% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.5% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.8% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.8% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,582,296,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,582,253,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,576,388,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,576,374,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,565,006,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 5,486 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 5,149 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 4,966 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 5,350 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 5,291 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 2
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceutical Businessreportable segment | employees | at 2023-03-31 | 49095 pure |
| Pharmaceutical Businessreportable segment | employees | at 2023-03-31 | 5486 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,742
| Item | Context | Value | Unit |
|---|---|---|---|
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)該当なし | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋本町二丁目１番１号(武田薬品工業株式会社武田グローバル本社) | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京(3278)2111(代表) | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)グローバルファイナンス チーフアカウンティングオフィサー＆コーポレートコントローラー 竹田 徳正 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00919 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45020 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)武田薬品工業株式会社 | |
| Filer name in english | FilingDateInstant | Takeda Pharmaceutical Company Limited | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Current fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Current period end date | FilingDateInstant | 2023-03-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2021-04-01 | |
| Comparative period end date | FilingDateInstant | 2022-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2022-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Overview of affiliated entities (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Business policy business environment issues to address etc (text) | FilingDateInstant | Text · Plus | |
| Disclosure of sustainability related financial information (text) | FilingDateInstant | Text · Plus | |
| Governance (text) | FilingDateInstant | Text · Plus | |
| Reference to other information governance | FilingDateInstant | Text · Plus | |
| Risk management (text) | FilingDateInstant | Text · Plus | |
| Reference to other information risk management | FilingDateInstant | Text · Plus | |
| Strategies metrics and targets (text) | FilingDateInstant | Text · Plus | |
| Reference to other information metrics and targets | FilingDateInstant | Original text (Japanese)2023年統合報告書「PATINET すべての患者さんのために」 | |
| Policy on human resource development and improvement of internal environment strategy (text) | FilingDateInstant | Text · Plus | |
| Description of metrics related to policy on human resource development and improvement of internal environment and targets and results using such metrics metrics and targets (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |